Zilico is developing the next generation of diagnostic devices that remove subjectivity, increase accuracy and deliver results in real-time.These characteristics allow for the improvement and extension of clinical screening programmes, globally.
Zilico’s product portfolio is centred on its patented Electrical Impedance Spectroscopy (EIS) technology which has applicability across a wide range of neoplastic conditions. The first application is focused on the early and accurate detection of Cervical Cancer.
